These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 6762414)

  • 1. Clinical pharmacokinetics of disopyramide.
    Karim A; Nissen C; Azarnoff DL
    J Pharmacokinet Biopharm; 1982 Oct; 10(5):465-94. PubMed ID: 6762414
    [No Abstract]   [Full Text] [Related]  

  • 2. Correlation of disopyramide pharmacokinetics with efficacy in ventricular tachyarrhythmia.
    Rangno RE; Warnica W; Ogilvie RI; Kreeft J; Bridger E
    J Int Med Res; 1976; 4(1 Suppl):54-8. PubMed ID: 1026530
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical pharmacology of disopyramide].
    Rewerski W; Dorociak A; Walczak F; Dobiasz A
    Pol Tyg Lek; 1980 Jul; 35(29):1109-12. PubMed ID: 7001399
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog.
    Karim A; Kook C; Novotney RL; Zagarella J; Campion J
    Drug Metab Dispos; 1978; 6(3):338-45. PubMed ID: 26556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disopyramide pharmacokinetics and bioavailability.
    Dubetz DK; Brown NN; Hooper WD; Eadie MJ; Tyrer JH
    Br J Clin Pharmacol; 1978 Sep; 6(3):279-81. PubMed ID: 687507
    [No Abstract]   [Full Text] [Related]  

  • 6. Disopyramide binding to serum protein in man and animals.
    Lima JJ; Haughey DB
    Drug Metab Dispos; 1981; 9(6):582-3. PubMed ID: 6120822
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics of disopyramide administered by intramuscular, intravenous and oral routes to normal volunteers [proceedings].
    Ashford JJ; Carmichael D; Kidner PH
    Br J Pharmacol; 1979 Jul; 66(3):442P-443P. PubMed ID: 526732
    [No Abstract]   [Full Text] [Related]  

  • 8. Disopyramide kinetics in renal impairment: determinants of interindividual variability.
    Burk M; Peters U
    Clin Pharmacol Ther; 1983 Sep; 34(3):331-40. PubMed ID: 6883909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition kinetics of disopyramide in patients with renal insufficiency.
    Shen DD; Cunningham JL; Shudo I; Azarnoff DL
    Biopharm Drug Dispos; 1980; 1(3):133-40. PubMed ID: 7448340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of concentration-dependent protein binding on serum concentrations and urinary excretion of disopyramide and its metabolite following oral administration.
    Haughey DB; Lima JJ
    Biopharm Drug Dispos; 1983; 4(2):103-12. PubMed ID: 6882879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disopyramide in renal impairment.
    Whiting B; Elliott HL
    Lancet; 1977 Dec 24-31; 2(8052-8053):1363. PubMed ID: 74774
    [No Abstract]   [Full Text] [Related]  

  • 12. The influence of protein binding on disopyramide clearance.
    Bryson SM; Lawrence JR; Steele WH; Campbell BC; Elliott HL; Sumner DJ
    Eur J Clin Pharmacol; 1982; 23(5):453-6. PubMed ID: 7151851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetic study of disopyramide in normal man].
    Mallein R; Rondelet J; Boucherat M; Ksavrelof M; Pignat M
    Therapie; 1978; 33(4):463-73. PubMed ID: 734626
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative bioavailability of disopyramide after multiple dosing with standard capsules and controlled-release tablets.
    Forssell G; Graffner C; Nordlander R; Nyquist O
    Eur J Clin Pharmacol; 1980; 17(3):209-13. PubMed ID: 7363933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disopyramide pharmacokinetics during recovery from myocardial infarction.
    Bryson SM; Cairns CJ; Whiting B
    Br J Clin Pharmacol; 1982 Mar; 13(3):417-21. PubMed ID: 7059444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical pharmacology of anti-arrhythmia agents. I. Quinidine, procainamide and disopyramide].
    Witkowska M
    Kardiol Pol; 1981; 24(7):505-17. PubMed ID: 7024612
    [No Abstract]   [Full Text] [Related]  

  • 17. Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability.
    Bryson SM; Whiting B; Lawrence JR
    Br J Clin Pharmacol; 1978 Nov; 6(5):409-19. PubMed ID: 728284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disopyramide hemodialysis and kinetics in patients requiring long-term hemodialysis.
    Sevka MJ; Matthews SJ; Nightingale CH; Izard MW; Fieldman A; Chow MS
    Clin Pharmacol Ther; 1981 Mar; 29(3):322-6. PubMed ID: 7471602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disopyramide in acute myocardial infarction: problems with changing pharmacokinetics.
    Elliott HL; Thomson AH; Bryson SM
    Eur J Clin Pharmacol; 1986; 30(3):345-7. PubMed ID: 3732373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.
    Giacomini KM; Swezey SE; Turner-Tamiyasu K; Blaschke TF
    J Pharmacokinet Biopharm; 1982 Feb; 10(1):1-14. PubMed ID: 7069575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.